NCT00253539View on ClinicalTrials.gov

Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
Breast CancerHereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions
DRUG

arzoxifene hydrochloride

Given orally

DRUG

tamoxifen citrate

Given orally

OTHER

placebo

Given orally

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

The Cleveland Clinic

OTHER

NCT00253539 - Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer | Biotech Hunter | Biotech Hunter